2023 Guidance and Q3 Earnings

Delivering growth across portfolio Q3 2023: positive performance across Vaccines and Specialty Medicines and all regions Sales contribution by product area¹ Sales contributions by region¹ Sales (Em) Specialty Medicines Vaccines 9,000 8,000 +7% 7,000 6,000 5,000 4,000 3,000 2,000 1,000 GSK Q3 2022 US Europe International ■General Medicines 9,000 +16% 8,000 +7% -2% 7,000 6,000 +17% Sales (£m) 5,000 4,000 3,000 2,000 +34% 1,000 Q3 2023 Absolute values at AER; changes at CER, unless stated otherwise 1. Excluding COVID-19 solutions +16% +17% +5% +19% 0 Q3 2022 Q3 2023 14

View entire presentation